Gleason分级分组5前列腺癌的转录组异质性
研究对2138例GG5前列腺癌根治术标本转录组数据分析,识别出4个共识聚类,其中一个聚类(325例,15.2%)富集细胞周期/增殖、代谢、雄激素反应和DNA修复相关基因,AGR较高(p<0.001)。该高风险聚类在1921例和201例队列中验证,后者显示高风险聚类患者无远处转移生存显著更差。
要点
- GG5前列腺癌存在转录组异质性,可分4个分子亚型。
- 高基因组风险聚类占15.2%,AGR更高且无远处转移生存更差。
- 该高风险聚类可能从治疗强化中获益更多。
核心结论
- GG5前列腺癌转录组异质性显著,识别出高基因组风险聚类,其无远处转移生存更差。
研究设计与样本
- 回顾性转录组数据分析,发现队列2138例GG5前列腺癌根治术患者,验证队列1921例和201例。
主要发现
- 发现4个共识聚类,基于标志通路差异转录激活、分子亚型谱和平均基因组风险(AGR)区分。
- 一个聚类含325例(15.2%),富集细胞周期/增殖、代谢、雄激素反应和DNA修复基因,AGR高于其他聚类(p<0.001)。
- 该高风险聚类在1921例和201例队列中验证,后者显示高风险聚类患者无远处转移生存显著更差。
关键数值与推荐
- 高风险聚类AGR高于其他聚类,p<0.001。
- 高风险聚类占GG5人群15.2%(325/2138)。
临床怎么用
- GG5前列腺癌患者可考虑转录组分子分型,识别高基因组风险聚类以指导治疗强化决策。
局限性
- 原文未报告具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gleason grade group (GG) 5 prostate cancer has been associated with an aggressive natural history, and retrospective data support a role for treatment intensification. However, clinical outcomes remain heterogeneous in this cohort, and intensified treatments carry an increased risk of adverse events. We sought to explore the transcriptomic heterogeneity of GG 5 tumors by querying transcriptomic data from the tumors of 2138 patients with GG 5 disease who underwent prostatectomy. Four distinct consensus clusters were identified with respect to differential transcriptional activation of hallmark pathways, with distinct molecular subtyping profiles and different average genomic risks (AGRs). One cluster, accounting for 325 tumors (15.2% of the population), was enriched for genes related to the cell cycle/proliferation, metabolic pathways, androgen response pathways, and DNA repair, and had a higher AGR than the other clusters (p < 0.001). This clustering, with an identification of a high genomic risk cluster, was subsequently validated in a separate cohort of 1921 patients as well as a third cohort of 201 patients. The latter cohort had outcomes available, and it was found that patients in the high genomic risk cluster had significantly worse distant metastasis-free survival than the other clusters. Tumors in this high genomic risk cluster of GG 5 disease may be particularly likely to benefit from treatment intensification. PATIENT SUMMARY: In this report, we examined differences in gene expression in tumors from men with Gleason grade group 5 prostate cancer. We identified significant diversity, with one specific subgroup of tumors associated with expression profiles that suggest a worse prognosis.
引用
- Kishan AU, Romero T, Alshalalfa M, et al. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020. PMID: 32461072. doi:10.1016/j.eururo.2020.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。